2024-05-22 16:00:00 ET
Sona Nanotech (CSE:SONA,OTCQB:SNANF) is ramping up clinical trials for its targeted hyperthermia therapy (THT) for cancer. CEO David Regan said the company is looking forward to taking THT into in-human studies after interim results from its efficacy study on animals showed statistically significantly superior results .
“We went into this study with a simple hypothesis that our THT for cancer would shrink cells and … tumors from the inside out … But we found something more interesting along the way,” he said.
“We've seen in this study it’s not just that the treated tumor shrinks, but that you're getting shrinkage in the untreated tumor. The theory behind that is that we're gently destroying the cancer cells through a process called apoptosis that generates new antigens. And those new antigens, we believe, are triggering a systemic effect. And that's what the second phase and our most recent news that came out are saying. It's changing the adaptive immune system of the animal, effectively serving as a vaccine.”
For further details see:
Sona Nanotech CEO Eyes In-human Studies as Animal Trials Show "Superior" Results